SWOG clinical trial number
S0816
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Interim FDG-PET Imaging
Abbreviated Title
Phase II Stage III-IV Hodgkin's: FDG-PET Imaging Study
Treatment
Cyclophosphamide
Prednisone
Vincristine
Bleomycin
Doxorubicin
DTIC
Etoposide
Vinblastine Sulfate
Procarbazine
ABVD
BEACOPP
Pts must have untreated Stage III or IV classical Hodgkin lymphoma (nodular sclerosing, mixed cellularity, lymphocyte-rich or lymphocyte depleted. Nodular lymphocyte predominant Hodgkin is not eligible. Adequate sections and paraffin block from original diagnostic specimen must be available for central review submission. Pts must be offered participation in correlative science. Pts must be age 18-60, inclusive. Pts must have bidimensionally measurable disease. Pts must have unilateral or bilateral bm biopsy. Pts must have CT scan of chest/abdomen and pelvis, and baseline FDG-PET scan. Pts must not have prior chemotherapy, radiation or antibody therapy for lymphoma. Pts must have Zubrod PS of 0-2. Serum erythrocyte sedimentation rate (ESR), LDH, hemoglobin, albumin, WBC and lymphocytes must be measured. Pts with history of hypertension or cardiac symptoms must have MUGA or ECHO with no significant abnormalities and cardiac EF >/= 45%. Pts must not be sero-positive for Hep B or Hep C. Pts who are immune to Hep B are eligible. HIV status must be known prior to reg. HIV+ pts must not have multi-drug resistant HIV, CD4 counts <350/mcl or other concurrent AIDS-defining conditions. Pts must not have significant lung disease with abnormal LFTs (DLCO >25% below predicted after correction for hemoglobin) unless attributable to lymphoma. Pts must not require continuous supplemental oxygen. Pts must not have prior solid organ transplant. Pts must not have prior malignancy except adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer (currently in complete remission) or any other cancer from which the pt has been disease-free for 5 years. Pts must not be pregnant or nursing. Women/men of reproductive potential must agree to use effective contraception during study and for at least 6 months after completion of therapy.
2022
ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (CHL) PATIENTS WITH A POSITIVE INTERIM-PET DEAUVILLE SCORE 5 AFTER 2 ABVD CYCLES: A POOLED ANALYSIS OF INDIVIDUAL PATIENT DATA OF THREE MULTICENTER TRIALS
S Viviani;C Pavoni;S Barrington;L Guerra;H Schoder;P Johnson;A Kirkwood;D Stephens;J Friedberg;S Chauvie;M Knopp;M Federico;G Emblad;A Rossi;P Corradini;A Gallamini;A Rambaldi;C Tarella International Symposium on Hodgkin Lymphoma (October 22-24, 2022, Cologne, Germany), poster
2021
New prognostic score incorporating MTV predicts treatment failure in advanced Hodgkin Lymphoma
S Barrington;A Kirkwood;L Pike;C Guezennec;H Li;M Leblanc;D Poon;M Knopp;L Clifton-Hadley;C Laubach;H Schoder;JW Friedberg;P Johnson International Conference on Malignant Lymphoma 2021 (tentative June 2021), oral
Classical Hodgkin lymphoma [Review]
P Brice;E de Kerviler;J Friedberg Lancet, Jan 22;S0140-6736(20)32207-8. doi: 10.1016/S0140-6736(20)32207-8. Online ahead of print
PMid: PMID33493434
